Teva Plans To Take Skinny-Label Defeat To Supreme Court
Company Confirms It Will Seek Review Of GSK Labeling Carve-Outs Litigation In US
Executive Summary
Following the decision by the US Court of Appeals for the Federal Circuit not to rehear “en banc” Teva’s litigation with GSK revolving around skinny-label generic carvedilol, the Israeli company has confirmed that it will seek Supreme Court review of the ruling.